摘要
目的:通过对氟桂利嗪胶囊在临床使用中的安全性信息进行总结,分析氟桂利嗪胶囊所致的不良反应/事件(ADR/ADE)的规律和特点,为临床合理用药提供参考,促进医疗机构提升安全、合理用药水平,减少严重ADR/ADE的发生。方法:检索数据库近十年关于氟桂利嗪胶囊致ADR/ADE的病例报道,对患者的不良反应发生时间、不良反应表现及累及损伤系统、用法用量等进行回顾性分析。结果:ADR/ADE发生时间以1-6个月最多,占比94.74%;ADR累及多个系统/器官,主要以各类神经系统疾病(76.60%)为主。结论:临床使用氟桂利嗪胶囊过程中应注意加强用药监测,尤其注意迟发型ADR/ADE的发生,定期随访,减少ADR/ADE的发生。
Objective:To summarize the safety information of Flunarizine capsules in clinical use,and analyze the rules and characteristics of adverse reactions/events(ADR/ADE)caused by Flunarizine capsules,so as to provide reference for clinical rational drug use,promote medical institutions to improve the level of safe and rational drug use,and reduce the occurrence of severe ADR/ADE.Methods:Case reports of ADR/ADE caused by Flunbrizine capsules were retrieved from databases in recent ten years,and the occurrence time,adverse reaction manifestations,damage system,usage and dosage of patients were retrospectively analyzed.Results:The time of OCCURRENCE of ADR/ADE was 1-6 months,accounting for 94.74%.ADR involves a number of systems/organs,mainly various types of nervous system diseases(76.60%).Conclusion:In the clinical use of Flunarizine capsule,attention should be paid to strengthen drug monitoring,especially the occurrence of delayed ADR/ADE,regular follow-up to reduce the occurrence of ADR/ADE.
作者
徐霜
许威
张玮
赵世丹
刘悦
徐博学
Xu Shuang(Center for Drug Evaluation and Risk Monitoring of Heilongjiang Province,Harbin Heilongjiang 150020)
出处
《黑龙江医药》
CAS
2021年第4期820-822,共3页
Heilongjiang Medicine journal
关键词
氟桂利嗪
安全性
不良反应
Flunarizine
safety
Mechanisms
adverse reaction
